Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: ESAIY )

10.29 -0.02 (-0.19%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 28, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 90,995
Open 10.22
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 10.31
Today's Range 10.03 - 10.31
52wk Range 9.310 - 18.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi. 
Via Benzinga
Exposures Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety

Performance

YTD
-16.71%
-16.71%
1 Month
-1.81%
-1.81%
3 Month
+2.85%
+2.85%
6 Month
-17.10%
-17.10%
1 Year
-38.66%
-38.66%

More News

Read More
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
Via Investor's Business Daily
Exposures Product Safety
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Via InvestorPlace
Topics Economy
Exposures Economy
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
Via Investor's Business Daily
Current Analysis: Eisai Co Ltd (ESAIY)
Via Talk Markets
Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
Via Investor's Business Daily
Topics Earnings
Exposures Financial
3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
Via InvestorPlace
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
Via Investor's Business Daily
Exposures Product Safety
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
Via InvestorPlace
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Via Talk Markets
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
Via InvestorPlace
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Via Investor's Business Daily
3 Aging Population Stocks to Profit from the Boomer Generation
Via InvestorPlace
Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
Via Benzinga
Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
Via Investor's Business Daily
3 Biotech Moonshots to Bet on the Future of Health
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
The 3 Best Biotech Stocks to Buy Now: September 2023
Via InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
Via InvestorPlace
All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings
Via Investor's Business Daily
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
Via Benzinga
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
Via Investor's Business Daily
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
Via Investor's Business Daily
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.